N-(2-(3,4,5-trihydroxybenzamido)ethyl)-3,4,5-trihydroxybenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-(2-(3,4,5-trihydroxybenzamido)ethyl)-3,4,5-trihydroxybenzamide
• 英文别名: N,N'-bisgalloyl 1,2-diaminoethane；N,N'-1,2-ethanediylbis(3,4,5-trihydroxybenzamide)；N,N''-1,2-Ethanediylbis(3,4,5-trihydroxybenzamide)Hydrate；3,4,5-trihydroxy-N-[2-[(3,4,5-trihydroxybenzoyl)amino]ethyl]benzamide
• 化学式: C₁₆H₁₆N₂O₈
• 分子量: 364.312
• InChiKey: CUKAJLUIIBQEDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  180
• 氢给体数：
  8
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  N,N'-乙烷-1,2-二基二(3,4,5-三甲氧基苯酰胺) 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 生成 N-(2-(3,4,5-trihydroxybenzamido)ethyl)-3,4,5-trihydroxybenzamide
  参考文献：
  名称：

  Synthesis and in Vitro Evaluation of Two Progressive Series of Bifunctional Polyhydroxybenzamide Catechol-O-methyltransferase Inhibitors

  摘要：

  Two progressive series of molecules with two polyhydroxybenzamide substructures were synthesized and tested as potential inhibitors of catechol-O-methyltransferase (COMT). These compounds were designed for the purpose of enhanced enzyme binding with duplicated substructures separated by a linker section of various lengths. Our results show that potency and mode of inhibition observed with the ''bifunctional'' compounds were a reflection of their bifunctional nature. Furthermore, potency and mode of inhibition were dependent on the length of the linker section. Of the assayed compounds, the optimum linker was found to be diaminopropane. For example, N,N'-1,3-propanediylbis(3,4-dihydroxybenzamide) and N,N'-1,3-propanediylbis(3,4,5-trihydroxybenzamide) demonstrated strong inhibitory action against COMT, with apparent K-i values of 0.3 and 6.0 mu M, respectively.

  DOI：

  10.1021/jm9605187

文献信息

• Structure-Activity Relationship of Bis-Galloyl Derivatives Related to (-)-Epigallocatechin Gallate
  作者：Kosuke Dodo、Taro Minato、Yuichi Hashimoto

  DOI：10.1248/cpb.57.190

  日期：——

  Green tea and (−)-epigallocatechin gallate (EGCG: one of main components of green tea) are well known to have preventive activities against human cancers. Previously, using a galloyl group as a core structure derived from EGCG, we developed alkyl gallate and gallamide derivatives, which showed strong antiproliferative activity towards human leukemia HL-60 cells by inducing apoptosis. Here, as a further structural development study, we planned to introduce an additional galloyl group into alkyl gallates and gallamides. According to this strategy, various bisgallate and bisgallamide derivatives were synthesized and tested for antiproliferative activity towards HL-60 cells. In gallamide derivatives having a short alkyl chain, the additional galloyl group enhanced the antiproliferative activity. In contrast, in the gallate derivatives, the additional galloyl group had no effect on the antiproliferative activity.

  绿茶和（−）-表没食子酸没食子酯（EGCG：绿茶的主要成分之一）众所周知对人类癌症具有预防活性。之前，我们利用从EGCG衍生的没食子酰基作为核心结构，开发了烷基没食子酸酯和没食子酰胺衍生物，这些衍生物通过诱导细胞凋亡对人类白血病HL-60细胞表现出强的抗增殖活性。在这里，作为进一步的结构开发研究，我们计划在烷基没食子酸酯和没食子酰胺中引入额外的没食子酰基。根据这一策略，合成了多种双没食子酸酯和双没食子酰胺衍生物，并测试其对HL-60细胞的抗增殖活性。在具有短烷基链的没食子酰胺衍生物中，额外的没食子酰基增强了抗增殖活性。相反，在没食子酸酯衍生物中，额外的没食子酰基对抗增殖活性没有影响。
• Simple, Clean and Highly Efficient Synthesis of Polyphenolic Amides Catalysed by Ferric Exchanged Montmorillonite
  作者：Dhrubajyoti Mahanta、Jyotirekha G. Handique

  DOI：10.2174/157017811799304241

  日期：2011.11.1

  A mild, efficient and highly convenient protocol is reported for the synthesis of a series of polyphenolic amides using ferric exchanged montmorillonite as a strong solid acid catalyst. This heterogeneous catalyst has an advantage of a strikingly simple work up procedure over conventional homogeneous acids. The catalyst is recoverable and recyclable.

  报告采用铁交换蒙脱石作为强固酸催化剂，合成了一系列多酚酰胺，该方法温和、高效、操作简便。与传统的均相酸催化剂相比，这种异相催化剂的优点是操作过程非常简单。催化剂可回收和循环使用。
• Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism
  申请人：Lawrence Daniel A.

  公开号：US20100137194A1

  公开（公告）日：2010-06-03

  The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.

  本发明涉及纤溶酶原激活剂-1（PAI-1）抑制剂化合物及其在治疗任何与升高的PAI-1相关的疾病或病状中的应用。本发明包括但不限于使用这些化合物来调节脂质代谢并治疗与升高的PAI-1、胆固醇或脂质水平相关的病症。
• PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20160009748A1

  公开（公告）日：2016-01-14

  The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.

  本发明涉及纤溶酶原激活物-1（PAI-1）抑制剂化合物及其在治疗与升高的PAI-1相关的任何疾病或病况中的用途。本发明包括但不限于使用这样的化合物来调节脂质代谢并治疗与升高的PAI-1、胆固醇或脂质水平相关的病症。
• US9120744B2
  申请人：——

  公开号：US9120744B2

  公开（公告）日：2015-09-01